Cargando…

Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies

The short- and long-term morbidity and mortality in acute heart failure is still unacceptably high. There is an unmet need for new therapy options with new drugs with a new mode of action. One of the drugs currently in clinical testing in Phase III is ularitide, which is the chemically synthesized f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anker, Stefan D., Ponikowski, Piotr, Mitrovic, Veselin, Peacock, W. Frank, Filippatos, Gerasimos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368857/ https://www.ncbi.nlm.nih.gov/pubmed/25670819 http://dx.doi.org/10.1093/eurheartj/ehu484

Ejemplares similares

Randomized double‐blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta‐analysis
por: Mitrovic, Veselin, et al.
Publicado: (2018)

Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF
por: Voors, Adriaan A, et al.
Publicado: (2014)

Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry
por: Cowie, Martin R., et al.
Publicado: (2021)

Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
por: Nawrocka-Millward, Sylwia, et al.
Publicado: (2021)

The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
por: Comin-Colet, Josep, et al.
Publicado: (2013)

Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020)

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
por: Metra, Marco, et al.
Publicado: (2010)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023)

Clinical development plan for regenerative therapy in heart failure
por: Terzic, Andre, et al.
Publicado: (2016)

Acute Decompensated Heart Failure Update
por: Teerlink, John R, et al.
Publicado: (2015)

Nurse‐led ambulatory care supported by non‐invasive haemodynamic assessment after acute heart failure decompensation
por: Krzesiński, Paweł, et al.
Publicado: (2021)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure
por: Ponikowski, Piotr, et al.
Publicado: (2014)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Decompensated heart failure
por: Mangini, Sandrigo, et al.
Publicado: (2013)

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2013)

Iron Deficiency in Acute Decompensated Heart Failure
por: Beale, Anna, et al.
Publicado: (2019)

Hypoalbuminemia in Patients with Acute Decompensated Heart Failure
por: Imamura, Teruhiko
Publicado: (2019)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR‐HF substudy
por: Okonko, Darlington O., et al.
Publicado: (2019)

Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC)
por: Metra, Marco, et al.
Publicado: (2022)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Rationale and design of Ferinject(®) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
por: Anker, Stefan D., et al.
Publicado: (2009)

Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
por: Jankowska, Ewa A., et al.
Publicado: (2013)

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial
por: Anker, Stefan D., et al.
Publicado: (2015)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Heart failure guidelines implementation: Lifting barriers using registries and networks
por: Keramida, Kalliopi, et al.
Publicado: (2020)

Clinical significance of spleen stiffness in patients with acute decompensated heart failure
por: Saito, Yuki, et al.
Publicado: (2020)

Polypharmacy and Clinical Outcomes in Hospitalized Patients With Acute Decompensated Heart Failure
por: Ozasa, Neiko, et al.
Publicado: (2023)

Acute Heart Failure Registry: Risk Assessment Model in Decompensated Heart Failure
por: Delgado, Anne, et al.
Publicado: (2016)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1
por: Jankowska, Ewa A., et al.
Publicado: (2011)

Use of carperitide infusion for acutely decompensated heart failure
por: Morita, Yoshihisa, et al.
Publicado: (2012)

Lung Ultrasound in the Management of Acute Decompensated Heart Failure
por: Ang, Shiang-Hu, et al.
Publicado: (2012)

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
por: Njoroge, Joyce N., et al.
Publicado: (2021)

Acute Kidney Disease After Acute Decompensated Heart Failure
por: Chen, Jia-Jin, et al.
Publicado: (2022)

Iatrogenic Decompensated Heart Failure
por: Tran, Patrick, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b09lf2furg3bc468jae501nu39